10-QPeriod: Q2 FY2002

BIOGEN INC. Quarterly Report for Q2 Ended Jun 30, 2002

Filed August 14, 2002For Securities:BIIB

Summary

IDEC Pharmaceuticals Corporation reported significant revenue growth in the second quarter of 2002, driven by strong performance in its key product, Rituxan, and the initial sales of its newly approved product, Zevalin. Total revenues reached $97.1 million for the three months ended June 30, 2002, a substantial increase from $64.8 million in the same period of 2001. This revenue surge translated into improved profitability, with net income rising to $35.4 million, or $0.20 per diluted share, compared to $25.2 million, or $0.15 per diluted share, in the prior year's quarter. The company's financial position was further strengthened by a successful offering of $714.4 million in senior convertible notes, providing substantial liquidity. However, the company also incurred significant expenses related to the commercialization of Zevalin and ongoing research and development. Investors should monitor the continued market penetration of Zevalin and the ongoing growth of Rituxan, as well as the company's ability to manage its escalating operational expenses and potential legal challenges related to its products.

Key Highlights

  • 1Total revenues increased by 49.8% to $97.1 million for the three months ended June 30, 2002, compared to $64.8 million in the prior year period.
  • 2Net income grew by 40.7% to $35.4 million for the three months ended June 30, 2002, from $25.2 million in the same period of 2001.
  • 3Diluted earnings per share improved to $0.20 from $0.15 year-over-year for the three-month period.
  • 4The company successfully raised approximately $696.0 million in net proceeds from the issuance of senior convertible notes in April/May 2002.
  • 5Product sales, primarily from Zevalin, contributed $3.3 million in the current quarter, marking the initial commercial sales of this newly approved product.
  • 6Revenues from the unconsolidated joint business (primarily Rituxan co-promotion profits and royalties) increased significantly, indicating strong performance in key collaborations.

Frequently Asked Questions

The primary drivers of revenue growth were the significant increase in copromotion profits from Rituxan, the co-promotion of which is managed with Genentech, and the initial product sales of Zevalin, which received FDA approval in February 2002. Royalties from Rituxan sales outside the U.S. also showed substantial growth.

IDEC Pharmaceuticals significantly improved its liquidity by issuing approximately $696 million in net proceeds from senior convertible notes in April/May 2002. This influx of cash bolstered its cash and cash equivalents and securities available-for-sale. Simultaneously, the company used a portion of these proceeds to repurchase $135 million of its common stock for treasury. The long-term debt increased due to the issuance of these notes.

The company heavily relies on Rituxan sales for its revenue, making it vulnerable to adverse developments with that product. Successful commercialization of Zevalin in the U.S. and obtaining European approval are critical. Other significant risks include the potential inability to develop and commercialize new products, reliance on contract manufacturers, intense industry competition, intellectual property protection challenges (including ongoing patent litigation for both Rituxan and Zevalin), and the need for future capital raises.

The company expects to continue incurring substantial research and development expenses due to ongoing preclinical and clinical testing, program expansion, technology in-licensing, and regulatory-related costs. Selling, general, and administrative expenses are also expected to increase to support the commercialization of Zevalin, manufacturing capacity, clinical trials, and intellectual property protection. The delay in European approval for Zevalin has also impacted revenue expectations from milestones.